Shares of Novavax surged over 20% higher on Thursday following the announcement of a settlement in a contentious arbitration dispute with Gavi, a global vaccine organization. The dispute arose after Novavax terminated a purchase agreement with Gavi in 2022, citing Gavi’s failure to procure the agreed-upon 350 million vaccine doses for the COVAX Facility. Gavi… Continue reading Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase

The approval of two gene therapies for sickle cell disease offers hope to patients, particularly Black individuals and people of color disproportionately affected by the condition. However, ensuring equitable access to these costly treatments presents a significant challenge for health officials. Despite the breakthrough, patients like Michael Goodwin remain hesitant due to the intensive medical… Continue reading New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle

Novavax experienced a significant surge of approximately 20% in its shares following the announcement of a settlement with Gavi, a global vaccine organization, regarding a dispute over a canceled Covid vaccine purchase agreement. As part of the settlement, Novavax could potentially pay up to $475 million to Gavi, although the actual amount may vary depending… Continue reading Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer’s Disease. The… Continue reading Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease

The healthcare landscape in the U.S. presents a challenging environment for physicians, characterized by burnout, staffing shortages, and administrative burdens, as revealed by a recent survey commissioned by Athenahealth. Over 90% of physicians experience burnout regularly, mainly attributed to excessive administrative tasks, with paperwork overwhelming 64% of doctors. More than 60% have contemplated leaving the… Continue reading Nearly all doctors feel burnout, but many are encouraged by potential of AI, survey says

The launch of the Alzheimer’s drug Leqembi by Biogen and Eisai has faced a slow start despite increasing demand. As the first drug approved to slow Alzheimer’s progression in the U.S., Leqembi signifies a significant advancement for over 6 million older Americans afflicted with the disease. Biogen, in particular, sees Leqembi as crucial for driving… Continue reading Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start

AbbVie has announced the appointment of Robert Michael as its new CEO, succeeding Richard Gonzalez, effective July 1. Michael, currently AbbVie’s president and chief operating officer, will become the company’s second-ever CEO, while Gonzalez will retire and transition to the role of executive chairman. Gonzalez led AbbVie since its spinoff from Abbott Laboratories in 2013,… Continue reading AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez

The rising demand for GLP-1 drugs for weight loss among consumers has posed a challenge for many U.S. companies navigating health insurance coverage for their employees. Despite the hefty price tag of typically $1,000 to $1,500 a month, drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are increasingly sought after. While some employers offer… Continue reading Most employer health plans don’t cover new blockbuster weight loss drugs, but that’s going to change

The Federal Trade Commission (FTC) has announced an investigation into the involvement of drug wholesalers and purchasing companies in the United States healthcare system regarding shortages of generic drugs, which are crucial for the majority of Americans’ prescriptions. This initiative comes in response to a significant shortfall in essential medicines over the past year, ranging… Continue reading Biden administration examining role of supply chain middlemen in generic drug shortages

The dismissal of a lawsuit by a major pharmaceutical industry lobbying group, along with two other organizations, marks an early victory for the Biden administration in its efforts to allow Medicare to negotiate prices for expensive prescription drugs. The decision supports a key policy aimed at making medications more affordable for seniors, potentially impacting pharmaceutical… Continue reading Federal judge tosses lobbying group’s lawsuit challenging Medicare drug price negotiations

Biogen’s fourth-quarter financial report revealed a decline in both revenue and profit compared to the previous year, attributed in part to charges associated with discontinuing its controversial Alzheimer’s drug, Aduhelm, and a decrease in sales of its multiple sclerosis therapies. The company reported $2.39 billion in revenue for the quarter, down 6% from the same… Continue reading Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies

Defense Secretary Lloyd Austin was taken back to the hospital on Sunday due to symptoms possibly related to a bladder issue, prompting him to transfer his responsibilities to his deputy. Austin, who is battling prostate cancer and has been recovering from surgery, initially retained all his duties upon entering the hospital. However, he later passed… Continue reading Defense Secretary Lloyd Austin hospitalized for bladder issue, transfers duties to deputy